CD86 and neoplasm: Blockade of CTLA4 has been shown to increase the infiltrative T cell and decrease Treg response to tumor cells (Curran et al., 2010) by allowing the co-stimulatory receptor CD28 to bind CD80 (B7.1) and CD86 (B7.2) expressed on antigen-presenting cells (APC) (Linsley et al., 1994).